Received 13 September 2001/Returned for modification 24 October 2001/Accepted 17 December 2001
|
|
- Jessica Stevenson
- 5 years ago
- Views:
Transcription
1 INFECTION AND IMMUNITY, Apr. 2002, p Vol. 70, No /02/$ DOI: /IAI Copyright 2002, American Society for Microbiology. All Rights Reserved. Vaccination of Guinea Pigs with DNA Encoding the Mycobacterial Antigen MPB83 Influences Pulmonary Pathology but Not Hematogenous Spread following Aerogenic Infection with Mycobacterium bovis Mark A. Chambers, 1 * Ann Williams, 2 Graham Hatch, 2 Dolores Gavier-Widén, 3 Graham Hall, 4 Kris Huygen, 5 Douglas Lowrie, 6 Philip D. Marsh, 2 and R. Glyn Hewinson 1 TB Research Group, Department of Bacterial Diseases, 1 and Department of Pathology, 3 Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey, KT15 3NB, Research Division 2 and Pathology, 4 CAMR, Salisbury, SP4 0JG, and NIMR, Mill Hill, London, 6 United Kingdom and Department of Virology, Pasteur Institute, B-1180 Brussels, Belgium 5 Received 13 September 2001/Returned for modification 24 October 2001/Accepted 17 December 2001 Protection of cattle against bovine tuberculosis by vaccination could be an important control strategy in countries where there is persistent Mycobacterium bovis infection in wildlife and in developing countries where it is not economical to implement a tuberculin test and slaughter control program. The main aim of such a vaccination strategy would be to reduce transmission of infection by reducing the lung pathology caused by infection and preventing seeding of the organism to organs from which M. bovis could be excreted. Recent reports of successful DNA vaccination against Mycobacterium tuberculosis in small-animal models have suggested that DNA vaccines act by reducing lung pathology without sensitizing animals to tuberculin testing. We therefore evaluated the ability of vaccines consisting of DNA encoding the mycobacterial antigens MPB83 and 85A to reduce lung pathology and prevent hematogenous spread in guinea pigs challenged with a low dose of aerosolized M. bovis. Vaccination with MPB83 DNA reduced the severity of pulmonary lesions, as assessed by histopathology, and resembled M. bovis BCG vaccination in this respect. However, unlike BCG vaccination, MPB83 DNA vaccination did not protect challenged guinea pigs from hematogenous spread of organisms to the spleen. In contrast, vaccination with antigen 85A DNA, a promising DNA vaccine for human tuberculosis, had no measurable protective effect against infection with M. bovis. * Corresponding author. Mailing address: TB Research Group, Department of Bacterial Diseases, Veterinary Laboratories Agency Weybridge, New Haw, Addlestone, Surrey, KT15 3NB, United Kingdom. Phone: (44) Fax: (44) m.a.chambers@vla.defra.gsi.gov.uk. Present address: Division of Wildlife, SVA (National Veterinary Institute), S Uppsala, Sweden. It has been estimated that more than 50 million cattle are infected with Mycobacterium bovis worldwide and that the resulting economic losses are approximately $3 billion (40). In developed countries pasteurization of milk and control of bovine tuberculosis (TB) by test- and slaughter-based control measures have dramatically reduced the transmission of M. bovis infection from cattle to humans. In these countries M. bovis is now predominantly an occupational zoonosis with potential risk for workers on farms, in abattoirs, and in zoos (13, 19, 37). In contrast, human TB caused by M. bovis is still a major health issue in many developing countries (11, 12, 14, 20). A number of factors maintain the threat of bovine TB to human health, including the increase in the number of immunocompromised individuals (20), the emergence of strains of M. bovis resistant to known drugs (33), and, in some countries, an increasing prevalence of disease in cattle (25). In countries with little or no wildlife reservoir, test and slaughter strategies have proved to be extremely successful in controlling bovine TB. However, this approach has been less successful in countries with significant reservoirs of M. bovis in their wildlife populations, and the cost of such a strategy precludes its use in many low-income countries. In these countries vaccination may be the only available option for the control of bovine TB. In Great Britain, a recent independent scientific review for the government of the recent sharp rise in bovine TB concluded that the best prospect for future control of the disease is to develop a vaccine to protect cattle against M. bovis infection (25). There are two main goals of vaccinating cattle against TB. The first is to prevent the establishment of infection in animals that are exposed to the organism, and the second is to prevent transmission of infection to other animals within a herd. In countries where tuberculin testing is used to control TB in cattle, either vaccination would need to be so effective that subsequent exposure to M. bovis did not sensitize animals to tuberculin or differential diagnostic tests would be required to distinguish vaccinated animals from animals infected with M. bovis (6, 44). In developing countries where tuberculin testing is not used to control M. bovis infection in cattle, the principal requirement of a vaccine would be to prevent transmission of the infection. While the goal of preventing establishment of infection may be difficult to achieve by vaccination, the goal of reducing transmission is less stringent and may be achievable by reducing lung pathology and preventing seeding of the organism to organs from which M. bovis could be excreted. In cattle, lesions are predominantly found in the lungs or lymph nodes of the thorax (30). A lowdose intratracheal challenge model has been established with cattle for testing vaccine efficacy; in this model the main readout is reduction in the number and severity of tuberculous 2159
2 2160 CHAMBERS ET AL. INFECT. IMMUN. lesions in the lungs and thoracic lymph nodes (6). Recent advances in DNA vaccination indicate that it may be possible to produce a vaccine that is active against M. bovis in cattle and reduces lung pathology without sensitizing the animals to the tuberculin skin test (2, 43). Such a vaccine would allow continued use of tuberculin-based strategies to remove animals that are not protected by vaccination. Mycolyl transferase (antigen 85A [Ag85A]) (4) and MPB83, a lipoglycoprotein of unknown function (21), are major antigens of Mycobacterium tuberculosis and M. bovis during infection (21, 27, 31, 36). In a number of studies, vaccination of mice and guinea pigs with DNA encoding Ag85A resulted in strong cellular immune responses and protection against challenge with M. tuberculosis (2, 3, 22, 41, 42). Evaluation of vaccination with DNA encoding MPB83 has been more limited, but recent studies revealed immune responses in both mice and cattle following vaccination and protection of mice against challenge with M. bovis (7) and M. tuberculosis (29). Recently, it was shown that the prolonged survival of Ag85A DNA-vaccinated guinea pigs following aerogenic challenge with M. tuberculosis resulted from less severe pulmonary pathology rather than a reduction in the bacterial load in the lungs or spleen (2). The authors therefore suggested that assessments of the protective efficacy of vaccines other than M. bovis BCG should include assessments of long-term survival and pathology, as well as assessments of reductions in organ bacterial load. In the present study, we evaluated vaccines consisting of DNA encoding Ag85A and MPB83 for their ability to protect guinea pigs challenged aerogenically with a low dose of M. bovis. Challenge with M. bovis caused extensive infiltration of lymphocytes into the lungs of unvaccinated guinea pigs. Like BCG vaccination, vaccination with either DNA construct provided significant protection against this lymphocytic infiltration. In addition, vaccination with DNA encoding MPB83 reduced the extent of granulomatous inflammation and caseation following aerogenic challenge with M. bovis, which also resembled an effect of BCG vaccination. However, unlike BCG vaccination, DNA vaccination did not reduce the load of acid-fast bacilli (AFB) in the lungs or protect challenged guinea pigs from hematogenous spread of organisms to the spleen. MATERIALS AND METHODS DNA constructs. Plasmid pcmv-83 was made by inserting the mpt83 gene (which has a sequence identical to that of the mpb83 gene from M. bovis [21]) from M. tuberculosis H37Rv into the plasmid backbone pcmv4 as described previously (7). Plasmid pcmv4 is based on plasmid vector pcdna3.1 from Invitrogen (Leek, The Netherlands), with addition at the HindIII restriction site of intron A from the human cytomegalovirus immediate-early gene (10). The control plasmid pcmv-link was made by removing mpt83 from pcmv-83 as described previously (7). Plasmid pvr a encoding Ag85A from M. tuberculosis and its plasmid vector, pvr1020, have been described previously (41). DNA used for immunization was prepared by using a QIAGEN-tip plasmid extraction kit and endotoxin-free buffers (QIAGEN Ltd., Dorking, United Kingdom) as recommended by the manufacturer. The DNA was resuspended in endotoxin-free phosphate-buffered saline (PBS) (Sigma, Poole, United Kingdom) prior to injection. Bacteria and media. Lyophilized M. bovis BCG Pasteur strain (obtained from the Statens Serum Institut, Copenhagen, Denmark) was cultured in 10 ml of M-ADC-TW broth (23) for 7 days and stored at 80 C in seed lots. The strain of M. bovis used in this study (AF2122/97) was isolated from a tuberculin test reactor cow in 1997 and was cultured at Veterinary Laboratories Agency Weybridge. For enumeration, BCG Pasteur was plated on Middlebrook 7H10 agar containing 0.2% (vol/vol) glycerol and 10% (vol/vol) Middlebrook oleic acidalbumin-dextrose-catalase (OADC) enrichment. M. bovis strain AF2122/97 was plated on Middlebrook 7H10 agar containing 4.16 mg of sodium pyruvate per ml and 10% (vol/vol) Middlebrook OADC enrichment. When necessary, serial dilutions of bacterial suspensions were prepared in water containing 0.05% (vol/vol) Tween 80 to maintain dispersion. Inoculation of guinea pigs. Outbred female Dunkin-Hartley guinea pigs that weighed between 350 and 450 g and were free of intercurrent infection were obtained from Charles River UK Ltd., Margate, United Kingdom. The guinea pigs (six animals per group) each received either 100 l of PBS or 100 g of a plasmid DNA vaccine in the biceps femoris muscle of both hind limbs on two occasions 3 weeks apart. For the BCG group, the concentration of the BCG vaccine was adjusted to CFU/ml immediately prior to injection and the cells were dispersed by brief sonication by using a CV18 converter fitted with a 3-mm-diameter tip attached to a Vibracell control unit (Sonics & Materials Inc., Danbury, Conn.) set at 20% power. The guinea pigs were injected subcutaneously in the nape with 250 l of the BCG preparation (representing an inoculum of approximately CFU) on the day of the second DNA injection. Aerosol infection of guinea pigs. Vaccinated guinea pigs were challenged with M. bovis strain AF2122/97 via the aerosol route 8 weeks after the last inoculation by using a modified version of the mobile Henderson apparatus (15), as previously described (45). A suspension containing approximately 10 6 CFU/ml was used in order to obtain an inhaled retained dose in the lungs of approximately 10 organisms (9). Postmortem examination of guinea pigs. Infected animals were killed with peritoneal overdoses of sodium pentobarbitone 10 weeks after challenge or when an individual had lost 20% of its maximal body weight (the humane end point), whichever was sooner. Examination was carried out immediately after death. For each animal an external assessment of the condition of the body was followed by gross internal examination of the neck region and the thoracic and abdominal cavities. The lungs with the trachea, heart, and tracheobronchial lymph nodes attached were removed and placed in 10% Formol-buffered saline for subsequent examination. The whole spleen was removed aseptically and placed in 5 ml of sterile distilled water for bacteriological assessment. Determination of pulmonary disease by using formalin-fixed tissue. The trachea, bronchi, and heart were dissected away prior to detailed examination of the fixed lungs from each animal. The number of visible lesions on the dorsal surface of all lobes was recorded on a diagram of the lungs along with the positions and sizes of the lesions and information about whether necrosis or consolidation was present. Sections were then cut from the lungs of each animal and used for histopathological evaluation. A section was prepared from the base of the left apical lobe and from the right diaphragmatic lobe of each lung; we made sure that each lobe was sectioned at the same position for every animal. Duplicate sections were stained with hematoxylin and eosin stain and with van Giesson stain in order to aid visualization of fibrous tissue. The two sections were scored in a blinded fashion for the following features: area of the section occupied by granulomatous inflammation (granuloma area); fibrosis; calcification; and necrosis (coagulative or caseous). Necrosis was described as coagulative when the architecture of the tissue was preserved. In contrast, if all tissue architecture was lost, the necrosis was termed caseous (5). The extent of lymphocytic infiltration in each section was also assessed, along with the distribution of the lymphocytes (perivascular and/or peribronchiolar, peripheral to the granuloma, or inside granulomas). The extent or severity of each feature was assigned a score ranging from0to4. Bacterial enumeration. Following Ziehl-Neelsen staining, approximate numbers of AFB were determined in the sections of lungs examined for histopathology. The following scoring system was used to describe the data: 0, no AFB observed in the entire section; 1, 1 to 15 AFB observed in the whole section; 2, AFB observed frequently and detected in most fields (at a magnification of 40) with necrosis; 3, AFB very numerous and aggregates of AFB. Spleens were homogenized in 5 ml of sterile distilled water by using a rotating blade macerator system. Viable counts were determined by using serial dilutions of the macerate, and preparations were examined after 4 weeks of incubation at 37 C for growth of mycobacteria. The limit of detection was 25 CFU. Statistical analyses. Appropriate statistical tests were used, and all data were analyzed by using the InStat software package (version 3.00; GraphPad, San Diego, Calif.). The Mann-Whitney nonparametric test was used when the data were not sampled from Gaussian distributions (see Table 1 and Fig. 3). One-way analysis of variance was used for some of the data (see Fig. 1).
3 VOL. 70, 2002 EVALUATION OF DNA VACCINES FOR M. BOVIS 2161 FIG. 1. Number of gross lesions on the dorsal surfaces of fixed lungs 10 weeks after challenge with a low-dose aerosol of M. bovis strain AF2122/97. Guinea pigs were vaccinated and then challenged 8 weeks later. Each point represents an individual animal. The bar indicates the mean value for each group. RESULTS Influence of vaccination on the number of gross pulmonary lesions. Animals were vaccinated with either pcmv-83 encoding MPB83, pvr a encoding Ag85A, or the control vector plasmids. Two additional groups of guinea pigs were vaccinated with BCG Pasteur and PBS. Eight weeks after the final vaccination all animals were exposed to a low-dose aerosol of M. bovis. One animal in the PBS group, two animals in the pvr1020-vaccinated group, and two animals in the pcmv-83-vaccinated group were killed at the humane end point before the end of the experiment. Bacteriological analysis was not performed on these animals. All remaining animals survived to 10 weeks after challenge and were then killed humanely and used to evaluate vaccine efficacy. Figure 1 shows the number of visible lesions on the dorsal surfaces of the fixed lungs. Although vaccination with pvr a, pcmv-83, and BCG reduced the mean numbers of lesions by 22, 27, and 56%, respectively, compared with that of the PBS control, these reductions were not statistically significant (as determined by analysis of variance). Influence of vaccination on pulmonary histopathology. To examine the pathology of the lungs in more detail, sections were cut from each animal at standardized positions, and a number of histopathological features were assessed in a blinded manner (Table 1). All test treatments reduced the extent of granulomatous inflammation compared with that of the PBS treatment, and the results obtained for the pcmv-83 and BCG groups were significantly different statistically. Representative examples of the histopathology observed in vaccinated animals and animals treated with PBS are shown in Fig. 2. Vaccination with both pcmv-83 and BCG also reduced the extent of caseation within granulomas. Only BCG vaccination reduced the load of AFB and the amounts of calcification, fibrosis, and necrosis apparent histologically, which supported the gross assessment made with lesions. There was a marked difference between groups in terms of the extent of lymphocytic infiltration. All three vaccinated groups had less-extensive lymphocytic infiltration per section than the controls (Fig. 2), and the differences were significant statistically, very significant in the case of pcmv-83 (P , as determined by the Mann-Whitney test). Although there were fewer lymphocytes, careful examination revealed that a greater proportion of the lymphocytes in the pcmv-83- vaccinated animals were located within granulomas rather than peripherally or perivascularly (data not shown). This was not observed for granulomas present in guinea pigs vaccinated with either of the other vaccines. Vaccination with pcmv-83 did not reduce hematogenous spread of M. bovis. The bacterial loads in the spleens of all animals that survived to the end of the experiment were determined (Fig. 3). Only vaccination with BCG reduced the number of bacteria in the spleens (P 0.005, as determined by the Mann-Whitney test). The bacterial counts for three of the six animals vaccinated with BCG were below the limit of detection (25 CFU). These animals also had the fewest gross lung lesions (Fig. 1). The remaining three BCG-vaccinated animals had an average reduction in bacterial load compared with that of the PBS control of 1.7 log 10. Neither vaccination with pvr a nor vaccination with pcmv-83 prevented hematogenous spread of bacteria from the lungs to the spleens. TABLE 1. Semiquantitative assessment of the histopathology and bacterial load of guinea pig lungs a Group Granuloma area b Necrosis c Caseation Fibrosis Calcification Lymphocytes d AFB e PBS 3.00 (0.74) 1.92 (1.06) 1.08 (1.17) 1.00 (0.00) 0.96 (1.05) 1.89 (0.36) 1.33 (0.49) pvr (0.67) 1.50 (0.88) 1.33 (1.16) 1.21 (0.50) 0.79 (1.01) 1.42 (0.60) 1.17 (0.39) pvr a 2.33 (0.98) 1.96 (1.18) 1.33 (1.30) 1.08 (0.29) 0.88 (0.98) 1.28 (0.39) f 1.33 (0.49) pcmv-link 2.00 (1.48) 1.25 (1.12) 1.25 (1.42) 0.96 (0.62) 0.96 (1.27) 1.11 (0.78) 0.92 (0.67) pcmv (1.34) g 1.96 (0.81) 0.71 (1.05) 1.33 (0.49) 0.88 (1.30) 0.95 (0.63) h 1.46 (0.84) BCG 1.25 (1.29) f 0.88 (1.09) g 0.25 (0.45) 0.71 (0.75) 0.08 (0.19) g 0.92 (0.92) g 0.50 (0.52) f a The extent or severity of each parameter was assigned a score ranging from 0 to 4. The mean value for each group was derived from two sections for each animal. The values in parentheses are standard deviations. b Area of section occupied by granulomatous inflammation. c Coagulative necrosis. Caseous necrosis was scored separately. d Extent of lymphocytic infiltration, regardless of the distribution within the section. e AFB, as determined by Ziehl-Neelsen staining, were scored as follows: 0, no AFB observed in the entire section; 1, 1 to 15 AFB observed in the whole section; 2, AFB observed frequently and detected in most fields (at a magnification of 40) with necrosis; 3, AFB very numerous and aggregates of AFB. f P 0.005, as determined by the Mann-Whitney test. g P 0.05, as determined by the Mann-Whitney test. h P , as determined by the Mann-Whitney test.
4 2162 CHAMBERS ET AL. INFECT. IMMUN. DISCUSSION DNA vaccines for TB, based on expression of selected mycobacterial antigens, have advantages over live vaccines in a number of respects. Such vaccines should be safer for immunocompromised individuals, quality control should be easier, and at the same time it should be possible to remove irrelevant or suppressive antigens. Another advantage is that studies to date have shown that unlike BCG vaccination, DNA vaccination does not sensitize guinea pigs or cattle to the tuberculin skin test (2, 43), which would allow continued use of tuberculin with vaccinated animals. Most importantly, a number of vaccines consisting of DNA encoding a single antigen or combined antigens have shown promising efficacy against TB in smallanimal models (22, 24, 28, 29, 41, 42). In this study we evaluated two candidate DNA vaccines for bovine TB. The vaccine consisting of DNA encoding Ag85A was chosen because it has been shown to protect mice and guinea pigs against M. tuberculosis (2, 3, 22, 41). The vaccine consisting of DNA encoding MPB83 was chosen because MPB83 is an immunodominant antigen of M. bovis (21, 31, 36) and a vaccine consisting of DNA encoding this antigen has been shown to protect mice to some extent against challenge with M. bovis (7) and M. tuberculosis (29). This is the first report of evaluation of DNA vaccines for M. bovis with a guinea pig low-dose infection model. Vaccination with DNA encoding MPB83 and Ag85A reduced the number of pulmonary lesions visible postmortem, although the reduction was not statistically significant for either vaccine. A more detailed study of the histopathology of the lungs of vaccinated and control guinea pigs revealed that vaccination with DNA encoding MPB83 reduced the extent of granulomatous inflammation and caseation to levels intermediate between the levels obtained with controls and the levels obtained with BCG vaccination, as shown in Fig. 2. Similar effects of vaccination on these parameters, as shown by histopathological assessment, have been reported by other workers (2, 39). Little or no reduction in the levels of these parameters was observed following vaccination with DNA encoding Ag85A. FIG. 2. Representative micrographs of guinea pig lungs, showing the reduction in granulomatous inflammation in the BCG-vaccinated (A) and pcmv-83-vaccinated (B) groups compared with the pvr a-vaccinated group (C) and the PBS control (D). Vaccination with BCG or pcmv-83, but not vaccination with pvr a, reduced both the number and the size of the granulomas, as reflected in the pathology scores shown in Table 1. The sections were given the following scores for granuloma size: panel A, 1.00; panel B, 1.00; panel C, 2.00; and panel D, These photographs also demonstrate the marked reductions in the numbers of lymphocytes observed in the three vaccinated groups compared with the control. The sections were given the following scores for lymphocytic infiltration: panel A, 1.00; panel B, 0.67; panel C, 1.00; and panel D, Bar 400 m.
5 VOL. 70, 2002 EVALUATION OF DNA VACCINES FOR M. BOVIS 2163 FIG. 3. Ability of vaccines to protect guinea pigs from hematogenous spread following aerogenic challenge with M. bovis. Guinea pigs were vaccinated and then challenged 8 weeks later. The numbers of CFU recovered from the spleens of animals 10 weeks after challenge are shown (limit of detection, 25 CFU). The bars indicate the median values. Statistical significance was demonstrated by using the Mann- Whitney nonparametric test. In vaccination studies in which Ag85A and BCG were used to protect against M. tuberculosis aerosol challenge in guinea pigs, enhanced lymphocyte infiltration into tuberculous lesions was found to correlate with protection against M. tuberculosis (2). In contrast, we did not observe increased lymphocytic infiltration in the lungs of vaccinated animals following aerosol challenge with M. bovis. In fact, the opposite was observed. Since lymphocytes accumulate progressively in the developing tuberculous granulomas (1, 32), the observed difference may have been due to the fact that we examined tissue sections at least 5 weeks earlier than the tissue sections were examined in the M. tuberculosis study (2). However, although we assessed protection of the guinea pigs earlier in this study, the animals still developed the full spectrum of pulmonary pathology described for challenge with M. tuberculosis (2), including necrosis, caseation, fibrosis, and calcification. In fact, the protracted progression of M. tuberculosis pathology in guinea pigs appears to be temporally compressed in M. bovis infections (34, 35). The lower level of lymphocyte infiltration may also reflect differences in the immune responses to M. bovis and M. tuberculosis infections, as suggested by recent comparative studies (8, 45). The histopathology data support the view that the BCG and MPB83 vaccines retarded the progress of granuloma development, and this may also account for the reduction in lymphocytic infiltration (Fig. 2). The ability to prevent hematogenous spread is a recognized feature of BCG vaccination (17, 26, 38). In this study, only BCG vaccination was able to prevent the dissemination of bacteria to the spleen and to reduce the load of AFB in the lungs; the latter finding was determined histologically. In previous studies, we demonstrated that vaccination with BCG confers a profound level of protection against colonization of the spleen by M. bovis 5 weeks after challenge and that the counts obtained with all spleens were below the lower limit of detection (8). In this study we found that one-half of the BCG-vaccinated guinea pigs still exhibited a high level of protection 10 weeks after challenge. Enumeration of the gross lung lesions (Fig. 1) suggested that in the other half pulmonary protection had waned, which allowed organisms to escape and colonize the spleen. The greater variability in the number of spleen CFU at 10 weeks following aerosol infection than in the number of spleen CFU at 5 weeks following aerosol infection probably resulted from the stochastic nature of the seeding of the spleen with bacteria from the lungs following the breakdown of local protective immunity. The inability of Ag85A DNA vaccination to reduce the bacterial load in the lungs and spleens of guinea pigs challenged with M. tuberculosis has been reported previously (2). However, in the previous study the vaccine consisting of DNA encoding Ag85A mediated a protective effect through reduced pulmonary pathology, which led to enhanced survival of the animals. In the present study, Ag85A vaccination provided little or no protection against the pulmonary pathology caused by aerogenic challenge with M. bovis, although there are a number of differences between the two studies. We used M. bovis for challenge rather than M. tuberculosis, so it is possible that the greater virulence of M. bovis for guinea pigs (18) masked any protective effect of Ag85A vaccination. Another difference is that we used plasmid pvr a vaccine, whereas Baldwin and coworkers used pv1jns-85a vaccine (2). This difference is unlikely to account for the difference in the efficacy of Ag85A DNA vaccination since both plasmids contain the same promoter, secretion signal, and drug resistance marker gene. Moreover, the two DNA vaccines have been found to be equally efficacious in mice (41, 42). A principal difference between the two studies is that we used half the concentration of vaccine DNA that Baldwin and colleagues used and we administered it on two occasions rather than three occasions. Also, expression of the Ag85 complex in M. tuberculosis may be different from expression of the Ag85 complex in M. bovis. Vaccination with MPB83 DNA has been reported to protect mice against intravenous challenge with M. bovis (7) and aerogenic challenge with M. tuberculosis (29). The failure of the same vaccine to reduce the bacterial load in the lungs and spleens of guinea pigs could be due to the fact that guinea pigs are more susceptible to virulent mycobacteria than mice (18). Furthermore, the extents and natures of the immune response to MPB83 vaccination may be different in the two species. This has recently been reported for Ag85A: vaccination of cattle with DNA encoding this antigen failed to stimulate strong immune responses (43). We are currently performing vaccination and challenge studies with pcmv-83 in cattle. These studies should determine whether the mouse or the guinea pig is a better model for predicting the efficacy of candidate bovine TB vaccines in a natural host. At present, the protection provided by DNA vaccines against TB has not exceeded the protection provided by BCG. However, there is cause for optimism. It is hoped that understanding the fundamental nature of vaccine protection in animal models that reflect the natural host will enable more efficacious DNA vaccines to be developed. The fact that the DNA vaccines tested to date do not compromise the tuberculin test in cattle (43) makes them particularly attractive candidates for control of bovine TB. Alternatively, given the ability of the MPB83 DNA vaccine to reduce lung pathology caused by M. bovis, a vaccination strategy consisting of DNA priming and BCG boosting might prove to be a more effective way to
6 2164 CHAMBERS ET AL. INFECT. IMMUN. improve the protective efficacy of BCG against M. bovis challenge (16). However, since BCG sensitizes cattle to tuberculin, alternative diagnostic strategies would be required to implement this strategy. Recently, we and others have demonstrated that antigen or peptide cocktails based on ESAT-6 and CFP-10 used in a whole-blood gamma interferon assay can discriminate between M. bovis infection and BCG vaccination with a high degree of sensitivity and specificity (6, 44). Thus, the use of vaccination regimens consisting of DNA priming and BCG boosting may be feasible as long as the antigens used for diagnosis are not included in the vaccine. Finally, our observation that a DNA vaccine expressing Ag85A, which is a promising candidate vaccine for human TB, did not protect against challenge with M. bovis underlines the need for ongoing empirical testing of candidate vaccines for bovine TB. ACKNOWLEDGMENTS This work was funded by the Department for Environment, Food and Rural Affairs (formerly Ministry of Agriculture, Fisheries and Food, Great Britain) and by grant G from the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (to K.H.). We acknowledge the support of the animal services units at Veterinary Laboratories Agency Weybridge and CAMR. REFERENCES 1. Abe, Y., K. Sugisaki, and A. M. Dannenberg, Jr Rabbit vascular endothelial adhesion molecules: ELAM-1 is most elevated in acute inflammation, whereas VCAM-1 and ICAM-1 predominate in chronic inflammation. J. Leukoc. Biol. 60: Baldwin, S. L., C. D Souza, A. D. Roberts, B. P. Kelly, A. A. Frank, M. A. Lui, J. B. Ulmer, K. Huygen, D. M. McMurray, and I. M. Orme Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66: Baldwin, S. L., C. D. D Souza, I. M. Orme, M. A. Liu, K. Huygen, O. Denis, A. Tang, L. Zhu, D. Montgomery, and J. B. Ulmer Immunogenicity and protective efficacy of DNA vaccines encoding secreted and nonsecreted forms of Mycobacterium tuberculosis Ag85A. Tuber. Lung Dis. 79: Belisle, J. T., V. D. Vissa, T. Sievert, K. Takayama, P. J. Brennan, and G. S. Besra Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276: Boyd, W A text-book of pathology, 2nd ed. Henry Kimpton, London, United Kingdom. 6. Buddle, B. M Vaccination of cattle against Mycobacterium bovis. Tuberculosis (Edinburgh) 81: Chambers, M. A., H. Vordermeier, A. Whelan, N. Commander, R. Tascon, D. Lowrie, and R. G. Hewinson Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83. Clin. Infect. Dis. 30(Suppl. 3):S283-S Chambers, M. A., A. Williams, D. Gavier-Widen, A. Whelan, G. Hall, P. D. Marsh, B. R. Bloom, W. R. Jacobs, and R. G. Hewinson Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immun. 68: Chambers, M. A., A. Williams, D. Gavier-Widen, A. Whelan, C. Hughes, G. Hall, M. S. Lever, P. D. Marsh, and R. G. Hewinson A guinea pig model of low-dose Mycobacterium bovis aerogenic infection. Vet. Microbiol. 80: Chapman, B., R. Thayer, K. Vincent, and N. Haigwood Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19: Cosivi, O., J. M. Grange, C. J. Daborn, M. C. Raviglione, T. Fujikura, D. Cousins, R. A. Robinson, H. F. Huchzermeyer, I. de Kantor, and F. X. Meslin Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg. Infect. Dis. 4: Daborn, C. J., J. M. Grange, and R. R. Kazwala The bovine tuberculosis cycle -an African perspective. Soc. Appl. Bacteriol. Symp. Ser. 25: 27S-32S. 13. Dalovisio, J., M. Stetter, and S. Mikota-Wells Rhinoceros rhinorrhea: cause of an outbreak of infection due to airborne Mycobacterium bovis in zookeepers. Clin. Infect. Dis. 15: Dankner, W. M., N. J. Waecker, M. A. Essey, K. Moser, M. Thompson, and C. E. Davis Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine (Baltimore) 72: Druett, H. A A mobile form of the Henderson apparatus. J. Hyg. 67: Feng, C. G., U. Palendira, C. Demangel, J. M. Spratt, A. S. Malin, and W. J. Britton Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69: Fok, J. S., R. S. Ho, P. K. Arora, G. E. Harding, and D. W. Smith Host-parasite relationships in experimental airborne tuberculosis. V. Lack of hematogenous dissemination of Mycobacterium tuberculosis to the lungs in animals vaccinated with Bacille Calmette-Guerin. J. Infect. Dis. 133: Francis, J Tuberculosis in animals and man. Cassell & Co. Ltd., London, United Kingdom. 19. Georghiou, P., A. Patel, A. Konstantinos, J. Streeton, and P. Robinson Mycobacterium bovis as an occupational hazard in abattoir workers. Aust. N. Z. J. Med. 19: Grange, J. M., C. Daborn, and O. Cosivi HIV-related tuberculosis due to Mycobacterium bovis. Eur. Respir. J. 7: Hewinson, R., S. L. Michell, W. P. Russell, R. A. McAdam, and W. R. J. Jacobs Molecular characterization of MPT83: a seroreactive antigen of Mycobacterium tuberculosis with homology to MPT70. Scand. J. Immunol. 43: Huygen, K., J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, R. R. Deck, C. M. DeWitt, I. M. Orme, S. Baldwin, C. D Souza, A. Drowart, E. Lozes, P. Vandenbussche, J. P. Van Vooren, M. A. Liu, and J. B. Ulmer Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2: Jacobs, W. R., Jr., G. V. Kalpana, J. D. Cirillo, L. Pascopella, S. B. Snapper, R. A. Udani, W. Jones, R. G. Barletta, and B. R. Bloom Genetic systems for mycobacteria. Methods Enzymol. 204: Kamath, A. T., C. G. Feng, M. Macdonald, H. Briscoe, and W. J. Britton Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67: Krebs, J., R. Anderson, T. Clutton-Brock, I. Morrison, D. Young, and C. Donnelly Bovine tuberculosis in cattle and badgers. Report by the Independent Scientific Review Group. Ministry of Agriculture, Fisheries and Food, London, United Kingdom. 26. Lagranderie, M., P. Ravisse, G. Marchal, M. Gheorghiu, V. Balasubramanian, E. H. Weigeshaus, and D. W. Smith BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber. Lung Dis. 74: Launois, P., R. DeLeys, M. N. Niang, A. Drowart, M. Andrien, P. Dierckx, J. L. Cartel, J. L. Sarthou, J. P. Van Vooren, and K. Huygen T-cellepitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun. 62: Lowrie, D. B., C. L. Silva, M. J. Colston, S. Ragno, and R. E. Tascon Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15: Morris, S., C. Kelley, A. Howard, Z. Li, and F. Collins The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 18: Neill, S. D., J. M. Pollock, D. B. Bryson, and J. Hanna Pathogenesis of Mycobacterium bovis infection in cattle. Vet. Microbiol. 40: Newell, D. G., R. S. Clifton-Hadley, and C. L. Cheeseman The kinetics of serum antibody responses to natural infections with Mycobacterium bovis in one badger social group. Epidemiol. Infect. 118: Orme, I. M., and A. M. Cooper Cytokine/chemokine cascades in immunity to tuberculosis. Immunol. Today. 20: Palenque, E., V. Villena, M. Rebollo, M. Jimenez, and S. Samper Transmission of multidrug-resistant Mycobacterium bovis to an immunocompetent patient. Clin. Infect. Dis. 26: Ratcliffe, H. L Tuberculosis induced by droplet nuclei infection: pulmonary tuberculosis of predetermined initial intensity in mammals. Am. J. Hyg. 55: Ratcliffe, H. L., and V. S. Palladino Tuberculosis induced by droplet nuclei infection: initial homogeneous response of small mammals (rats, mice, guinea pigs, and hamsters) to human and to bovine bacilli and the rate and pattern of tubercle development. J. Exp. Med. 97: Rhodes, S. G., D. Gavier-Widen, B. M. Buddle, A. O. Whelan, M. Singh, R. G. Hewinson, and H. M. Vordermeier Antigen specificity in experimental bovine tuberculosis. Infect. Immun. 68: Robinson, P., D. Morris, and R. Antic Mycobacterium bovis as an occupational hazard in abattoir workers. Aust. N. Z. J. Med. 18: Rodrigues, L. C., V. K. Diwan, and J. G. Wheeler Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22: Smith, D. W., and E. H. Wiegeshaus What animal models can teach us about the pathogenesis of tuberculosis in humans. Rev. Infect. Dis. 11(Suppl. 2):S385-S Steele, J. H Regional and country status reports -introduction, p In Mycobacterium bovis infection in animals and humans. Iowa State University Press, Ames.
7 VOL. 70, 2002 EVALUATION OF DNA VACCINES FOR M. BOVIS Tanghe, A., O. Denis, B. Lambrecht, V. Motte, T. van den Berg, and K. Huygen Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect. Immun. 68: Tanghe, A., P. Lefevre, O. Denis, S. D Souza, M. Braibant, E. Lozes, M. Singh, D. Montgomery, J. Content, and K. Huygen Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J. Immunol. 162: Vordermeier, H. M., P. J. Cockle, A. O. Whelan, S. G. Rhodes, M. A. Chambers, D. Clifford, K. Huygen, R. Tascon, D. Lowrie, M. J. Colston, and R. G. Hewinson Effective DNA vaccination of cattle with the mycobacterial antigens MPB83 and MPB70 does not compromise the specificity of the comparative intradermal tuberculin skin test. Vaccine 19: Vordermeier, H. M., A. Whelan, P. J. Cockle, L. Farrant, N. Palmer, and R. G. Hewinson Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin. Diagn. Lab. Immunol. 8: Williams, A., A. Davies, P. D. Marsh, M. A. Chambers, and R. G. Hewinson Comparison of the protective efficacy of Bacille Calmette-Guerin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin. Infect. Dis. 30(Suppl. 3):S299-S301. Editor: S. H. E. Kaufmann
Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG
INFECTION AND IMMUNITY, Feb. 2004, p. 1065 1071 Vol. 72, No. 2 0019-9567/04/$08.00 0 DOI: 10.1128/IAI.72.2.1065 1071.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Paucibacillary
More informationT-Cell Epitope Mapping of the Three Most Abundant Extracellular Proteins of Mycobacterium tuberculosis in Outbred Guinea Pigs
INFECTION AND IMMUNITY, May 1999, p. 2665 2670 Vol. 67, No. 5 0019-9567/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. T-Cell Epitope Mapping of the Three Most Abundant
More informationMedical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia
Medical Bacteriology- Lecture 10 Mycobacterium Actinomycetes Nocardia 1 Mycobacterium Characteristics - Large, very weakly gram positive rods - Obligate aerobes, related to Actinomycetes - Catalase positive
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationPathology of pulmonary tuberculosis. Dr: Salah Ahmed
Pathology of pulmonary tuberculosis Dr: Salah Ahmed Is a chronic granulomatous disease, caused by Mycobacterium tuberculosis (hominis) Usually it involves lungs but may affect any organ or tissue Transmission:
More informationMedical Bacteriology- lecture 13. Mycobacterium Actinomycetes
Medical Bacteriology- lecture 13 Mycobacterium Actinomycetes Mycobacterium tuberculosis Large, very weakly gram positive rods, Obligate aerobes, related to Actinomycetes, non spore forming, non motile
More informationA DNA Prime-Mycobacterium bovis BCG Boost Vaccination Strategy for Cattle Induces Protection against Bovine Tuberculosis
INFECTION AND IMMUNITY, Sept. 2003, p. 4901 4907 Vol. 71, No. 9 0019-9567/03/$08.00 0 DOI: 10.1128/IAI.71.9.4901 4907.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. A DNA
More informationPerspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2010, p. 781 794 Vol. 23, No. 4 0893-8512/10/$12.00 doi:10.1128/cmr.00005-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Perspectives on
More informationPulmonary Necrosis Resulting from DNA Vaccination against Tuberculosis
INFECTION AND IMMUNITY, Apr. 2003, p. 2192 2198 Vol. 71, No. 4 0019-9567/03/$08.00 0 DOI: 10.1128/IAI.71.4.2192 2198.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Pulmonary
More informationEvaluation of New Vaccines in the Mouse and Guinea Pig Model of Tuberculosis
INFECTION AND IMMUNITY, June 1998, p. 2951 2959 Vol. 66, No. 6 0019-9567/98/$04.00 0 Copyright 1998, American Society for Microbiology Evaluation of New Vaccines in the Mouse and Guinea Pig Model of Tuberculosis
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant
More informationMichael Santosuosso, Sarah McCormick, Xizhong Zhang, Anna Zganiacz, and Zhou Xing*
INFECTION AND IMMUNITY, Aug. 2006, p. 4634 4643 Vol. 74, No. 8 0019-9567/06/$08.00 0 doi:10.1128/iai.00517-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Intranasal Boosting
More informationEffect of oral exposure of Mycobacterium avium intracellular on the protective immunity induced by BCG
J. Biosci., Vol. 10, Number 4, December 1986, pp. 453-460. Printed in India. Effect of oral exposure of Mycobacterium avium intracellular on the protective immunity induced by BCG SUJATHA NARAYANAN, C.
More informationMonitoring tuberculosis progression using MRI and stereology
Monitoring tuberculosis progression using MRI and stereology TB the problem Estimated number of new cases in 2007 2 million deaths; 9 million new cases p.a. TB kills someone every 15 secs, 9,153 cases
More informationMycobacteria & Tuberculosis PROF.HANAN HABIB & PROF ALI SOMILY DEPRTMENT OF PATHOLOGY, MICROBIOLOGY UNIT COLLEGE OF MEDICINE
Mycobacteria & Tuberculosis PROF.HANAN HABIB & PROF ALI SOMILY DEPRTMENT OF PATHOLOGY, MICROBIOLOGY UNIT COLLEGE OF MEDICINE Objectives l Recognize that tuberculosis as a chronic disease mainly affecting
More informationTuberculosis. By: Shefaa Q aqa
Tuberculosis By: Shefaa Q aqa Tuberculosis is a communicable chronic granulomatous disease caused by Mycobacterium tuberculosis. It usually involves the lungs but may affect any organ or tissue in the
More informationTUBERCULOSIS IN EUROPEAN BADGERS (MELES MELES) AND THE CONTROL OF INFECTION WITH BACILLE CALMETTE-GUÉRIN VACCINATION
TUBERCULOSIS IN EUROPEAN BADGERS (MELES MELES) AND THE CONTROL OF INFECTION WITH BACILLE CALMETTE-GUÉRIN VACCINATION Authors: L. A. L. Corner, D. Murphy, E. Costello, and E. Gormley Source: Journal of
More informationExperiment #1 TARGET Mouse Model Group. Report prepared by Paul Converse, Ph.D. and Eric Nuermberger, M.D. March 1, 2006
Protocol for in vivo evaluation of growth rates and pathogenesis of M. tuberculosis strains found to have rapid or slow growth phenotypes in an in vitro model Experiment #1 TARGET Mouse Model Group Report
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationTuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
More informationField Evaluation of the Efficacy of Mycobacterium bovis Bacillus Calmette-Guérin against Bovine Tuberculosis in Neonatal Calves in Ethiopia
CLINICAL AND VACCINE IMMUNOLOGY, Oct. 2010, p. 1533 1538 Vol. 17, No. 10 1556-6811/10/$12.00 doi:10.1128/cvi.00222-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Field Evaluation
More informationA Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire.
Company LOGO A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire. Fayaz Ahmad Mir, Stefan H. E. Kaufmann,
More informationNew tools for control of bovine tuberculosis in cattle
New tools for control of bovine tuberculosis in cattle Bryce Buddle AgResearch, Hopkirk Research Institute Bovine tuberculosis (TB) in New Zealand Total cost of $100 million/year ($81 million TBfree NZ)
More informationGlobal progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationImmunologically Induced and Elicited Local
INFECTION AND IMMUNITY, Dec. 1970, p. 757-761 Copyright 1970 American Society for Microbiology Vol. 2, No. 6 Printed in U.S.A. Immunologically Induced and Elicited Local Resistance to Staphylococcus aureus
More informationMycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology
Mycobacterium tuberculosis Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology Robert Koch 1843-1910 German physician Became famous for isolating the anthrax bacillus (1877), tuberculosis bacillus (1882)
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationReceived 15 January 2008/Returned for modification 23 February 2008/Accepted 22 May 2008
INFECTION AND IMMUNITY, Aug. 2008, p. 3771 3776 Vol. 76, No. 8 0019-9567/08/$08.00 0 doi:10.1128/iai.00052-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Oral Vaccination of
More informationThe Enferplex TB test and the role of serology in TB diagnosis
The Enferplex TB test and the role of serology in TB diagnosis Alastair Hayton BVM&S DCHP MRCVS RCVS Specialist in Cattle health and Production Synergy Farm Health Ltd, Evershot, UK. Immune responses to
More informationCharacteristics of Mycobacterium
Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to
More informationReceived 6 April 2006/Returned for modification 11 May 2006/Accepted 4 July 2006
CLINICAL AND VACCINE IMMUNOLOGY, Sept. 2006, p. 1030 1036 Vol. 13, No. 9 1556-6811/06/$08.00 0 doi:10.1128/cvi.00134-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Cattle Husbandry
More informationGiovanni Delogu, Amy Li, Charlene Repique, Frank Collins, and Sheldon L. Morris*
INFECTION AND IMMUNITY, Jan. 2002, p. 292 302 Vol. 70, No. 1 0019-9567/02/$04.00 0 DOI: 10.1128/IAI.70.1.292 302.2002 DNA Vaccine Combinations Expressing Either Tissue Plasminogen Activator Signal Sequence
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor
More informationA PRELIMINARY TRIAL TO EVALUATE THE GAMMA- INTERFERON ASSAY FOR THE DETECTION OF TUBERCULOSIS IN CATTLE UNDER LOCAL CONDITIONS IN SERBIA
A PRELIMINARY TRIAL TO EVALUATE THE GAMMA- INTERFERON ASSAY FOR THE DETECTION OF TUBERCULOSIS IN CATTLE UNDER LOCAL CONDITIONS IN SERBIA I. PUŠIĆ 1, VESNA MILIĆEVIĆ 2, SARA SAVIĆ 1, JASNA PRODANOV 1, Ž.GRGIĆ
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationAIRBORNE INFECTION WITH MYCOBACTERIUM LEPRAE IN MICE
I N T ERN AT I ON ;\ L J OU RN AL OF L EPROSY Volume 44, Numbers I & 2 Primed ill the U. S.A. AIRBORNE INFECTION WITH MYCOBACTERIUM LEPRAE IN MICE R.J.W. Rees National Institute for Medical Research, London
More informationon Infectivity of Air on a Hospital Ward
Materials for Online Data Supplement for AJRCCM Surgical Face Masks Worn by Patients with Multidrug-Resistant Tuberculosis: Impact on Infectivity of Air on a Hospital Ward Authors: Ashwin S. Dharmadhikari
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationBCG: Past, Present and Future. Nwora Lance Okeke, MD, MPH August 24, 2016
BCG: Past, Present and Future Nwora Lance Okeke, MD, MPH August 24, 2016 Disclosures Nothing to disclose Overview Introduction and History Current Use Effectiveness Non-vaccine uses of BCG Edmond Nocard
More informationTUBERCULOSIS. Famous victims in their intellectual prime: Chopin, Paganini, Thoreau, Keats, Elizabeth Browning, Brontës
TUBERCULOSIS GENERAL Tuberculosis (TB) kills 1,700,000 annually worldwide. "The Captain of all the men of death that came to take him away was the consumption, for it was that which brought him down to
More informationBovine TB: the science-policy challenges
Bovine TB: the science-policy challenges Content England s TB strategy The TB problem Controlling the problem What would success look like? Measuring success 2 England s Bovine TB Strategy Aims to: Achieve
More informationOrder: Actinomycetales. Family: Mycobactericeae. Some are parasitic to cold blooded animal, others are saprophytic in nature.
Order: Actinomycetales Family: Mycobactericeae They are widely distributed in nature. Few no is pathogenic for man & animal. Some are parasitic to cold blooded animal, others are saprophytic in nature.
More informationLESSON ASSIGNMENT. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 6 Tuberculosis. TEXT ASSIGNMENT Paragraphs 6-1 through 6-11. LESSON OBJECTIVES After completing this lesson, you should be able to: 6-1. Identify the characteristics, signs/ symptoms,
More informationRespiratory System الفريق الطبي االكاديمي
Respiratory System الفريق الطبي االكاديمي Pathology sheet 5 Tuberculosis Done by: Ahmad Al-Sahele Introduction: as we know TB is caused by mycobacterium tubercolosis; now keep in your mind another microorganism
More informationMYCOBACTERIUM. Mycobacterium Tuberculosis (Mtb) nontuberculous mycobacteria (NTM) Mycobacterium lepray
MYCOBACTERIUM nontuberculous mycobacteria (NTM) Mycobacterium Tuberculosis (Mtb) Mycobacterium lepray 1-tubercle bacilli are thin 2- straight rods 3- obligate aerobes 4- derive energy from the oxidation
More informationP. Dandapat. Eastern Regional Station ICAR-Indian Veterinary Research Institute 37 Belgachia Road, Kolkata
Evaluation of the Sensitivity and Specificity of Gamma Interferon Assay, Single Intradermal Tuberculin and Comparative Intradermal Tuberculin Tests in Naturally Infected Cattle Herds P. Dandapat Eastern
More informationQ Fever What men and women on the land need to know
Q Fever What men and women on the land need to know Dr. Stephen Graves Director, Australian Rickettsial Reference Laboratory Director, Division of Microbiology, Pathology North (Hunter) NSW Health Pathology,
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationMYCOBACTERIA. Pulmonary T.B. (infect bird)
MYCOBACTERIA SPP. Reservoir Clinical Manifestation Mycobacterium tuberculosis Human Pulmonary and dissem. T.B. M. lepra Human Leprosy M. bovis Human & cattle T.B. like infection M. avium Soil, water, birds,
More informationSponsored document from Microbes and Infection / Institut Pasteur
Sponsored document from Microbes and Infection / Institut Pasteur The Syk/CARD9-coupled receptor Dectin-1 is not required for host resistance to Mycobacterium tuberculosis in mice Mohlopheni J. Marakalala
More informationSupplementary Material
Supplementary Material Supplementary Figure 1. NOS2 -/- mice develop an analogous Ghon complex after infection in the ear dermis and show dissemination of Mtb to the lung. (A) WT and NOS2 -/- mice were
More informationVeterinary Tuberculosis Vaccine Development
S223 Veterinary Tuberculosis Vaccine Development J. Frank T. Griffin From the Division of Immunology, Department of Microbiology, University of Otago, Dunedin, New Zealand Tuberculosis caused by Mycobacterium
More informationWANTED Manuscript supporting the prevailing paradigm of tuberculosis by any author DEAD or ALIVE $1,000 REWARD. 3 TB India HSCP
A New Paradigm for the Pathogenesis of Pulmonary Tuberculosis Bronchogenic tuberculosis The missing link between primary and post-primary disease Robert Hunter MD, PhD Dept. of Pathology and Laboratory
More informationTuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases
Tuberculosis - clinical forms Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases 1 TB DISEASE Primary Post-primary (Secondary) Common primary forms Primary complex Tuberculosis of the intrathoracic
More informationTuberculosis Elimination: The Role of the Infection Preventionist
Tuberculosis Elimination: The Role of the Infection Preventionist Preface: What Happens when Health Care Professionals are not familiar with TB? A 15 year old student was diagnosed with highly infectious
More informationDevelopment of a DIVA Skin-Test for Bovine Tuberculosis. Division, Stormont, Belfast, BT4 3SD, Northern Ireland.
JCM Accepts, published online ahead of print on 30 June 2010 J. Clin. Microbiol. doi:10.1128/jcm.00420-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationIntroduction. In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology.
Introduction In the past 15 years, several technological advancements have open new perspectives and applications in the field of vaccinology. - Genomics: fasten antigen discovery for complex pathogens
More informationThe non-human primate model in TB vaccine development
April 10, 2015 The non-human primate model in TB vaccine development Tom Evans MD Aeras Agenda Issues Transmission studies Recent advancements Outcomes Endpoint analysis Design Going forward 2 Development
More informationReactive Nitrogen Intermediates Have a Bacteriostatic Effect on Mycobacterium tuberculosis In Vitro
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3162 3166 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3162 3166.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Transmission and Pathogenesis of Tube rc ulos is U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for HIV/AIDS,
More informationTB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
More informationMycobacteriology William H. Benjamin, Jr.
Mycobacteriology William H. Benjamin, Jr. William H. Benjamin, PhD Department of Pathology UAB 1 Mycobacteria sp. Acid Fast Bacilli (AFB) Mycolic acids (C78-91) Waxes Obligate aerobes Slow growing days
More informationAntigen Mining with Iterative Genome Screens Identifies Novel Diagnostics for the Mycobacterium tuberculosis Complex
CLINICAL AND VACCINE IMMUNOLOGY, Jan. 2006, p. 90 97 Vol. 13, No. 1 1556-6811/06/$08.00 0 doi:10.1128/cvi.13.1.90 97.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Antigen
More informationTB Program Management San Antonio, Texas November 5-7, 2008
TB Program Management San Antonio, Texas November 5-7, 2008 Infection Control Lynelle Phillips, RN, MPH November 7, 2008 Infection Control Lynelle Phillips, RN MPH Nurse Consultant Heartland National TB
More informationEXPERIMENTAL SALMONELLOSIS
EXPERIMENTAL SALMONELLOSIS INTRACELLULAR GROWTH OF Salmonella enteritidis INGESTED IN MONONUCLEAR PHAGOCYTES OF MICE, AND CELLULAR BASIS OF IMMUNITY SUSUMU MITSUHASHI, ICHIEI SATO, AND TOKUMITSU TANAKA
More informationPossible steps to be taken:
Badgers are the most significant wildlife reservoir of bovine TB in the UK, followed by Red Deer in some areas such as Exmoor, and when the Wild Boar population increases they may also be a reservoir in
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationparticipation of FAO)*
Zoonotic tuberculosis (Mycobacterium bovis): Memorandum from a WHO meeting (with the participation of FAO)* In view of the considerable and continuing public health significance of Mycobacterium bovis
More informationPulmonary Lymphatics Are Primary Sites of Mycobacterium tuberculosis Infection in Guinea Pigs Infected by Aerosol
INFECTION AND IMMUNITY, Sept. 2006, p. 5397 5401 Vol. 74, No. 9 0019-9567/06/$08.00 0 doi:10.1128/iai.00332-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Pulmonary Lymphatics
More informationDiagnostic Value of Elisa Serological Tests in Childhood Tuberculosis
Diagnostic Value of Elisa Serological Tests in Childhood Tuberculosis by R. Dayal, a G. Sirohi, a M. K. Singh, a P. P. Mathur, a B. M. Agarwal, a V. M. Katoch, b B. Joshi, b P. Singh, b and H. B. Singh
More informationTuberculosis. Impact of TB. Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH)
Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 20 Tuberculosis Learning Objectives 1. Describe the biologic characteristics of the agent 2. Determine the epidemiologic characteristics
More informationHost-Pathogen Interactions in Tuberculosis
Host-Pathogen Interactions in Tuberculosis CNRS - Toulouse, France My presentation will focus on host-cell pathogen interactions in tuberculosis. However, I would first like offer a brief introduction
More informationHISTORY TB = 25% ADULT DEATHS EGYPTIAN MUMMIES: SPINAL TB. 17 th -18th CENTURIES- URBANIZATION MID 24
HISTORY EGYPTIAN MUMMIES: SPINAL TB 17 th -18th CENTURIES- URBANIZATION 19th CENTURY INDUSTRIALIZATION TB = 25% ADULT DEATHS GERM THEORY OF DISEASE KOCH S BACILLUS-1883 PRE-ANTIBIOTIC ERA SANATORIUM REGIMENS
More informationCurrent development in the diagnosis of tuberculosis
Current development in the diagnosis of tuberculosis Dr. Lucía de Juan Director of the EURL for Bovine Tuberculosis VISAVET Health Surveillance Centre dejuan@visavet.ucm.es Specific tasks : 1. Maximise
More informationHISTORY TB = 25% ADULT DEATHS MID 24 PRE-ANTIBIOTIC ERA
PRE-ANTIBIOTIC ERA SANATORIUM REGIMENS & REST CAVITARY DISEASE & COLLAPSE THERAPY FRESH AIR, SUNSHINE-ROOFTOPS SOLARIA HISTORY EGYPTIAN MUMMIES: SPINAL TB 17 th -18th CENTURIES- URBANIZATION 19th CENTURY
More informationMycobacterial Antigens Exacerbate Disease Manifestations in Mycobacterium tuberculosis-infected Mice
INFECTION AND IMMUNITY, Apr. 2002, p. 2100 2107 Vol. 70, No. 4 0019-9567/02/$04.00 0 DOI: 10.1128/IAI.70.4.2100 2107.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Mycobacterial
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationBovine TB: Epidemiology and Ecology of a Multi-Host Disease
Bovine TB: Epidemiology and Ecology of a Multi-Host Disease Christl Donnelly MRC Centre for Outbreak Analysis and Modelling Department of Infectious Disease Epidemiology Imperial College London (and in
More informationDevelopment and Evaluation of an Enzyme-Linked Immunosorbent Assay for Use in the Detection of Bovine Tuberculosis in Cattle
CLINICAL AND VACCINE IMMUNOLOGY, Nov. 2011, p. 1882 1888 Vol. 18, No. 11 1556-6811/11/$12.00 doi:10.1128/cvi.05343-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Development
More informationTuberculosis: The Essentials
Tuberculosis: The Essentials Kendra L. Fisher, MD, PhD THORACIC TUBERCULOSIS: THE BARE ESSENTIALS Kendra Fisher MD, FRCP (C) Department of Radiology Loma Linda University Medical Center TUBERCULOSIS ()
More informationAPPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS
APPLICATION OF IMMUNO CHROMATOGRAPHIC METHODS IN PLEURAL TUBERCULOSIS Hadizadeh Tasbiti.AR, Yari.SH, Bahrmand.AR, Karimi.A,Fateh.A, Sayfi.M Tuberculosis Dept.Pasteur Institute of Iran.Tehran.Iran 1 INTRODUCTION
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationResearch Article Cytokines as Biomarkers in the Diagnosis of MDR TB Cases
Cronicon OPEN ACCESS PULMONOLOGY AND RESPIRATORY MEDICINE Research Article Cytokines as Biomarkers in the Diagnosis of MDR TB Cases Nazish Fatima 1 *, Mohammad Shameem 2, Nabeela 1, Haris M Khan 1 1 Department
More informationHeparin binding haemagglutin as potential diagnostic marker of Mycobacterium bovis
NEW MICROBIOLOGICA, 31, 423-427, 2008 Heparin binding haemagglutin as potential diagnostic marker of Mycobacterium bovis Paola Molicotti 1, Alessandra Bua 1, Silvia Ortu 1, Maura C. Ladu 2, Giovanni Delogu
More informationTB Could Ruin Your Day (And Your Life)
TB Could Ruin Your Day (And Your Life) ONE COW HERD MANAGEMENT STANDARD OPERATING PROCEDURES Genetic Calf/Heifer Raising Dry Cow Maternity Transition Herd Health a. Vaccinations b. Udders Mastitis
More informationUse of the BacT/ALERT MB Mycobacteria Blood Culture System for Detecting ACCEPTED
JCM Accepts, published online ahead of print on December 00 J. Clin. Microbiol. doi:.11/jcm.011-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationIn the lungs, the organisms are taken up by macrophages and carried to lymph nodes. State one characteristic symptom of TB other than coughing.
1 Tuberculosis (TB) kills approximately three million people every year. Droplets containing the organisms that cause TB are released into the air when a person suffering from TB coughs. Transmission of
More informationEffect of Vaccine, Route, and Schedule on Antibody
APPUED MICROBIOLOGY, Mar. 1969, p. 355-359 Copyright 1969 American Society for Microbiology Vol. 17, No. 3 Printed in U.S.A. Effect of Vaccine, Route, and Schedule on Antibody Response of Rabbits to Pasteurella
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationReceived for publication February 8, 1960
EFFECT OF HOMOGENATES OF ORGANS FROM IMMUNIZED GUINEA PIGS ON THE RESPIRATION OF MYCOBACTERIUM TUBERCULOSIS' ANNE S. YOUMANS, GUY P. YOUMANS, AND ANDREW HEGRE, JR. Department of Microbiology, Northwestern
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationMODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit
MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit Topics to be covered What is Tuberculosis? TB bacteria and what is unique about it. How is TB different from HIV? How is TB
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationYersinia pestis. Yersinia and plague. Dr. Hala Al Daghistani
Yersinia pestis Dr. Hala Al Daghistani Yersinia species Short, pleomorphic gram-negative rods that can exhibit bipolar staining. Catalase positive, and microaerophilic or facultatively anaerobic. Animals
More informationBiology and Medicine
eissn: 09748369 Diagnosis of pulmonary tuberculosis by smear microscopy and culture in a tertiary health care facility Biology and Medicine SI Khatib, MT Williamson, R Singh, JM Joshi Accepted: 28 th Feb
More informationTuberculosis and Johne s Disease
Tuberculosis and Johne s Disease Prof. R. S. Chauhan Joint Director, Indian Veterinary Research Institute Izatnagar 243 122 (India) TUBERCULOSIS Tuberculosis is a chronic bacterial disease of animals caused
More information